What Does Retatrutide Do? Mechanism & UK Status Explained

Clinically Proven UK Registered Pharmacy

Retatrutide: Pros, Cons, Side Effects, UK Status

UK-registered clinical team
Confidential and secure
No GP visit needed
Fast and discreet delivery
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £10 off for new customers
Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment
£145.00 From £135.00 £10 discount using discount code Weightlossnew
LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen - UK-licensed prescription Treatment
Treatment

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00

Future orders save 5%
Start Assessment
Wegovy (Semaglutide) Weight Loss Injection - UK-licensed prescription Treatment
Treatment

Wegovy (Semaglutide) Weight Loss Injection

From £89.00

Future orders save 5%
Start Assessment
Saxenda - UK-licensed prescription Treatment
Treatment

Saxenda

From £68.00

Future orders save 5%
Start Assessment
Orlistat - UK-licensed prescription Treatment
Treatment

Orlistat

From £32.00

Future orders save 5%
Start Assessment
Xenical Orlistat 120mg Capsules - UK-licensed prescription Treatment
Treatment

Xenical Orlistat 120mg Capsules

From £49.99

Future orders save 5%
Start Assessment
Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER - UK-licensed prescription Treatment
Treatment

Wegovy® Oral Tablets (Semaglutide Pill): PRE-ORDER

From £83.00

Future orders save 5%
Start Assessment

What Does Retatrutide Do: Complete UK Guide

Understanding what does retatrutide do is essential for anyone following developments in weight management medication. Retatrutide is an investigational triple-agonist therapy that activates three hormone receptors simultaneously—GIP, GLP-1, and glucagon—to produce substantial weight loss in clinical trials. While not yet licensed in the UK, retatrutide represents the next generation of obesity pharmacotherapy, building upon the success of currently available treatments like tirzepatide and semaglutide.

What Does Retatrutide Do in the Body?

Retatrutide works through a unique triple-agonist mechanism, simultaneously activating glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors [1]. This distinguishes it from dual-agonist tirzepatide (GIP/GLP-1) and single-agonist semaglutide (GLP-1 only), both currently available at Cured Pharmacy.

The GIP and GLP-1 pathways reduce appetite, slow gastric emptying, and improve insulin secretion, whilst the glucagon component increases energy expenditure and promotes fat oxidation [1]. This triple mechanism addresses weight management through complementary pathways, potentially offering enhanced efficacy over existing treatments.

In phase 2 clinical trials, participants receiving the highest retatrutide dose (12mg weekly) achieved an average 24.2% body weight reduction at 48 weeks—the largest reduction observed in any obesity pharmacotherapy trial to date [2]. These results suggest what retatrutide does may represent a significant advance in medical weight management, though UK licensing remains pending MHRA approval.

Retatrutide Clinical Trial Results and Efficacy

The phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities [2]. Participants were randomised to receive subcutaneous retatrutide at varying doses (1mg, 4mg, 8mg, or 12mg weekly) or placebo for 48 weeks, alongside lifestyle intervention.

At the 12mg dose, mean weight reduction reached 24.2% from baseline, with 91% of participants achieving at least 5% weight loss and 75% achieving at least 15% weight loss [2]. Even the 8mg dose produced an average 17.5% reduction, substantially exceeding typical results with currently licensed treatments.

Secondary endpoints showed improvements in cardiometabolic markers, including HbA1c, fasting glucose, blood pressure, and lipid profiles [2]. These findings demonstrate what retatrutide does extends beyond weight reduction to comprehensive metabolic health benefits, though long-term cardiovascular outcome data remain under investigation.

Comparing Trial Outcomes Across Weight Loss Medications

Direct head-to-head trials between retatrutide and approved treatments have not been conducted, but indirect comparisons provide context. The SURMOUNT-1 trial of tirzepatide (available as Mounjaro at Cured Pharmacy from £135.00) showed 22.5% mean weight loss at the 15mg dose over 72 weeks [3]. The STEP-1 trial of semaglutide (available as Wegovy from £135.00) demonstrated 14.9% mean reduction at 2.4mg weekly over 68 weeks [4].

Whilst retatrutide's phase 2 results appear promising, the shorter trial duration (48 weeks versus 68-72 weeks) and smaller sample size mean definitive superiority claims require phase 3 confirmation. What retatrutide does in controlled trials may differ from real-world effectiveness, as observed with all weight management medications.

What Does Retatrutide Do: Advantages Over Current Treatments

The primary advantage of retatrutide lies in its triple-receptor mechanism, which theoretically addresses obesity through more pathways than dual or single agonists [1]. The addition of glucagon receptor activation may enhance energy expenditure and fat metabolism beyond what GIP/GLP-1 activation alone achieves.

Clinical trial data suggest retatrutide produces greater absolute weight reduction than any currently licensed obesity medication, with 24.2% mean loss at the highest dose [2]. This magnitude of effect approaches outcomes previously achievable only through bariatric surgery, potentially offering a pharmacological alternative for patients unsuitable for or declining surgical intervention.

The once-weekly subcutaneous injection format aligns with existing GLP-1 treatments, meaning administration convenience matches what patients already accept with tirzepatide and semaglutide. Retatrutide's tolerability profile in phase 2 trials appeared similar to other incretin-based therapies, predominantly gastrointestinal side effects of mild-to-moderate severity [2].

Treatment Mechanism Mean Weight Loss UK Status Starting Price
Retatrutide Triple agonist (GIP/GLP-1/Glucagon) 24.2% (48 weeks, phase 2) Not UK-approved Not available
Mounjaro (tirzepatide) Dual agonist (GIP/GLP-1) 22.5% (72 weeks) MHRA-licensed From £145
Wegovy (semaglutide) Single agonist (GLP-1) 14.9% (68 weeks) MHRA-licensed From £89
Saxenda (liraglutide) Single agonist (GLP-1) 8.0% (56 weeks) MHRA-licensed From £68
Orlistat Lipase inhibitor 3-5% (12 months) MHRA-licensed From £32

Potential Disadvantages and Limitations of Retatrutide

Retatrutide remains investigational and is not approved by the MHRA for use in the UK. Phase 3 trials are ongoing, and regulatory submission timelines have not been publicly confirmed. Patients seeking prescription weight management treatment today must consider currently licensed options available at Cured Pharmacy, including Mounjaro, Wegovy, or Saxenda.

The triple-agonist mechanism, whilst potentially advantageous, introduces theoretical complexity. Glucagon receptor activation raises questions about long-term metabolic effects, particularly regarding glucose homeostasis and hepatic function, which require extended safety monitoring beyond the 48-week phase 2 duration [1][2].

Cost projections for retatrutide, should it gain UK approval, remain speculative. Novel mechanisms and superior efficacy data typically command premium pricing. Current GLP-1 treatments range from competitive UK pricing for established options to higher costs for newer formulations, and retatrutide would likely position at the upper end of this spectrum.

Gastrointestinal Tolerability Concerns

In the phase 2 trial, gastrointestinal adverse events occurred in 60-80% of retatrutide recipients, predominantly nausea (58-73%), diarrhoea (33-48%), vomiting (27-48%), and constipation (17-29%) [2]. These rates align with other incretin-based therapies but remain substantial, potentially limiting real-world adherence.

Discontinuation due to adverse events occurred in 7-14% of retatrutide groups compared to 2% with placebo [2]. What retatrutide does to the gastrointestinal system mirrors mechanisms of currently available treatments—delayed gastric emptying and altered gut motility—suggesting similar tolerability challenges will persist despite the novel triple-agonist approach.

Common Side Effects: What Does Retatrutide Do to Cause Them?

The most frequent side effects of retatrutide stem directly from its mechanism of action. GLP-1 receptor activation slows gastric emptying, which reduces appetite but causes nausea, vomiting, and early satiety [1]. GIP receptor activity modulates these effects but does not eliminate them, whilst glucagon receptor activation may contribute to gastrointestinal motility changes.

Nausea typically peaks during dose escalation and diminishes with continued treatment, as observed with other incretin therapies [2]. Starting at lower doses and titrating gradually—the approach used in clinical trials—helps mitigate gastrointestinal symptoms. Most events were mild-to-moderate severity and did not require treatment discontinuation.

Hypoglycaemia risk appears low with retatrutide monotherapy in people without diabetes, consistent with the glucose-dependent mechanism of GIP and GLP-1 [2]. However, concomitant use with insulin or sulphonylureas would require dose adjustments, as with all incretin-based treatments. Injection site reactions occurred in approximately 10% of participants, similar to rates with tirzepatide and semaglutide [2].

UK Regulatory Status and What Does Retatrutide Do for Future Treatment Options

Retatrutide has not received marketing authorisation from the MHRA and cannot legally be prescribed, dispensed, or supplied in the UK outside of approved clinical trials. Phase 3 trials (TRIUMPH programme) are currently enrolling participants globally, with completion expected in 2025-2026, followed by regulatory submission [5].

UK patients seeking prescription weight management treatment today should consult with a UK prescriber about currently licensed options. At Cured Pharmacy, our clinical team provides free online consultations to assess suitability for tirzepatide (Mounjaro), semaglutide (Wegovy), liraglutide (Saxenda), or orlistat-based treatments, all of which have established efficacy and safety profiles approved by the MHRA.

Should retatrutide gain UK approval, it would join an expanding portfolio of pharmacological weight management options. Understanding what retatrutide does helps patients make informed decisions about their treatment journey, whether pursuing currently available therapies or monitoring developments in investigational medications. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and clinical team stay current with emerging treatments to provide evidence-based guidance as new options become available.

Accessing Weight Loss Treatment at Cured Pharmacy Today

Whilst retatrutide remains unavailable, Cured Pharmacy offers the UK's most effective licensed weight management medications with transparent upfront pricing and free clinical consultation. Mounjaro (tirzepatide), the first dual GIP/GLP-1 agonist, is available from £135.00 and represents the closest currently licensed comparator to retatrutide's multi-receptor approach.

All prescription weight loss treatments at Cured Pharmacy require online clinical assessment by a UK-registered prescriber, completed in under three minutes. We dispense only genuine UK-licensed medicines, with 100% discreet packaging and lowest prices guaranteed. Start your free consultation today to determine which treatment aligns with your medical history and weight management goals.

Scientific References

  1. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
  2. Jastreboff, A. M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972
  3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
  4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
  5. Eli Lilly and Company. (2024). A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-1). ClinicalTrials.gov Identifier: NCT05929313. https://clinicaltrials.gov/study/NCT05929313

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Retatrutide is not approved by the MHRA and cannot be prescribed or supplied in the UK.

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What does retatrutide do differently than Mounjaro or Wegovy?
Retatrutide activates three hormone receptors (GIP, GLP-1, and glucagon) simultaneously, whilst Mounjaro activates two (GIP/GLP-1) and Wegovy activates one (GLP-1). This triple mechanism produced 24.2% mean weight loss in phase 2 trials, compared to 22.5% with tirzepatide and 14.9% with semaglutide in their respective trials.
Is retatrutide available in the UK?
No, retatrutide has not received MHRA approval and cannot be legally prescribed or dispensed in the UK. Phase 3 trials are ongoing, with regulatory submission expected after 2025. Currently licensed alternatives include Mounjaro, Wegovy, Saxenda, and orlistat, all available at Cured Pharmacy.
What does retatrutide do to cause weight loss?
Retatrutide reduces appetite and slows gastric emptying through GIP and GLP-1 receptor activation, whilst simultaneously increasing energy expenditure and fat oxidation through glucagon receptor activation. This triple mechanism addresses obesity through complementary metabolic pathways.
What are the most common side effects of retatrutide?
Nausea (58-73%), diarrhoea (33-48%), vomiting (27-48%), and constipation (17-29%) were the most frequent side effects in clinical trials. These gastrointestinal effects typically diminish after the initial weeks of treatment and are similar to those experienced with other GLP-1-based medications.
How much weight can you lose with retatrutide?
In the phase 2 trial, participants receiving 12mg weekly retatrutide lost an average of 24.2% of their body weight over 48 weeks, with 91% achieving at least 5% weight loss. Individual results vary, and these outcomes were achieved alongside lifestyle intervention in a controlled trial setting.
What does retatrutide do that makes it better than current treatments?
Retatrutide's triple-receptor mechanism produced greater mean weight reduction (24.2%) than any currently licensed obesity medication in clinical trials. However, it remains investigational, and direct head-to-head trials against approved treatments have not been conducted, so definitive superiority claims require phase 3 confirmation.
Can I get retatrutide through Cured Pharmacy?
No, retatrutide is not approved by the MHRA and cannot be legally supplied in the UK. Cured Pharmacy dispenses only genuine UK-licensed medications. We offer currently approved alternatives including Mounjaro (tirzepatide) from £135.00 Wegovy (semaglutide) from £135.00 and other licensed weight management treatments, all requiring clinical assessment by a UK prescriber.
What does retatrutide do for people with diabetes?
Whilst retatrutide improved glycaemic markers in phase 2 obesity trials, it is currently being investigated specifically for type 2 diabetes management in separate clinical trials. The GIP, GLP-1, and glucagon pathways all influence glucose homeostasis, but UK licensing for diabetes indications would require dedicated efficacy and safety data.